Celcuity Inc (CELC) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[4], including 2 Phase 3[1], 1 Phase 2[2], 1 Phase 1[3].
Trial NCT06757634[5] evaluates Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant in Breast Cancer with a target enrollment of 674 participants. Trial NCT05501886[6] evaluates Gedatolisib in Breast Cancer with a target enrollment of 701 participants.
CELC has 1 Form 4 insider filing recorded at the SEC in the past 30 days[7].